Dublin, September. February 21, 2023 (Global News Service) — Research and Marketing Website Announced a comprehensive analysis of the oral antiviral drugs market, which is expected to grow at a CAGR of 2.1% from 2022 to 2031.
The Oral Antiviral Drugs Market by Indication, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031 report provides a comprehensive review of current trends, estimates, and market dynamics from 2021 to 2031. The oral antiviral drugs market includes drugs specifically designed to treat viral infections. Unlike most antibiotics, which destroy pathogens, antiviral drugs inhibit the development of pathogens by targeting different stages of the virus’s life cycle.
The significant increase in viral infections, especially influenza, HIV, and hepatitis is driving the market growth. The Centers for Disease Control and Prevention (CDC) 2022 report highlighted 9 million cases of influenza, resulting in 4 million doctor visits and 10,000 hospitalizations. Market growth is further supported by the increasing prevalence of hepatitis and herpes globally.
In addition, there are several initiatives launched by government and non-governmental organizations to increase awareness of viral diseases and available oral treatments. Increased adoption of advanced diagnostic technologies and an emphasis on diagnosing early viral infections such as hepatitis and HIV are also contributing factors. Key market players are noted to have adopted strategies such as collaborations, agreements, and alliances, which further boosts the market growth.
However, the high cost of oral antiviral drugs and the availability of vaccines for diseases such as influenza, hepatitis, and HPV may restrain market expansion. However, the growing demand for novel therapies and regulatory approvals provides significant opportunities for major market players.
In terms of segmentation, the oral antiviral drugs market is classified on the basis of indication, drug class, distribution channel, and region. Notably, the HIV segment, reverse transcriptase inhibitor drug category, and drugstore and retail pharmacy distribution channel dominated the revenue in 2021. Regionally, North America contributed the largest revenue in 2021, while Asia Pacific is expected to register the highest growth rate over the next decade.
Major players in the global oral antiviral drugs market include AbbVie, Amneal Pharmaceuticals LLC, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Merck & Co., Teva Pharmaceutical Industries Ltd. and Viatris Inc.
Main market segments
follow instructions
- hepatitis
- Human Immunodeficiency Virus (HIV)
- influenza
- others
By drug category
- Protease inhibitor
- reverse transcriptase inhibitor
- others
By distribution channel
- hospital pharmacy
- Pharmacies and retail pharmacies
- online provider
For more information about this report, please visit https://www.researchandmarkets.com/r/88jjtd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and latest trends.
-
Global oral antiviral drugs market